General MedicationsORALGeneric

PREDNISOLONE SODIUM PHOSPHATE

Standard Dose

EQ 30MG BASE

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview PREDNISOLONE SODIUM PHOSPHATE is listed in Drugs@FDA under application 202179 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient PREDNISOLONE SODIUM PHOSPHATE Form and strength TABLET, ORALLY DISINTEGRATING;ORAL - EQ 30MG BASE Sponsor RISING Submission history Latest submission status date: 2023-12-13 00:00:00.

Structured Monograph

Clinical summary

Approval overview PREDNISOLONE SODIUM PHOSPHATE is listed in Drugs@FDA under application 202179 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient PREDNISOLONE SODIUM PHOSPHATE Form and strength TABLET, ORALLY DISINTEGRATING;ORAL - EQ 30MG BASE Sponsor RISING Submission history Latest submission status date: 2023-12-13 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.